Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;28(10):1067-1072.
doi: 10.1007/s11916-024-01293-9. Epub 2024 Jul 5.

Diabetic Neuropathy: A Guide to Pain Management

Affiliations
Review

Diabetic Neuropathy: A Guide to Pain Management

Emily X Zhang et al. Curr Pain Headache Rep. 2024 Oct.

Abstract

Purpose of review: Diabetic neuropathy is a common complication of diabetes mellitus (DM) and can affect up to 50% of DM patients during their lifetime. Patients typically present with numbness, tingling, pain, and loss of sensation in the extremities. Since there is no treatment targeting the underlying mechanism of neuropathy, strategies focus on preventative care and pain management.

Recent findings: Up to 69% of patients with diabetic neuropathy receive pharmacological treatment for neuropathic pain. The United States Food and Drug Administration (FDA) confirmed four drugs for painful diabetic neuropathy (PDN): pregabalin, duloxetine, tapentadol, and the 8% capsaicin patch. Nonpharmacological treatments such as spinal cord stimulation (SCS) and transcutaneous electrical nerve stimulation (TENS) both show promise in reducing pain in DM patients. Despite the high burden associated with PDN, effective management remains challenging. This update covers the background and management of diabetic neuropathy, including its epidemiology, pathogenesis, preventative care, and current therapeutic strategies.

Keywords: Capsaicin; Duloxetine; Painful Diabetic Neuropathy; Pregabalin; Spinal Cord Stimulation; Tapentadol.

PubMed Disclaimer

References

    1. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5:41. Comprehensive review on diabetic neuropathy. - DOI - PubMed
    1. Taylor RS, Lad SP, White JL, Stauss TG, Healey BE, Sacks NC, et al. Health care resource utilization and costs in patients with painful diabetic neuropathy treated with 10 kHz spinal cord stimulation therapy. J Manag Care Spec Pharm. 2023;29:1021–9. Utilization of SCS resulted in lower rates of hospitalization and consequently lower health care costs. - PubMed - PMC
    1. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:136–54. - DOI - PubMed
    1. Albers JW, Pop-Busui R. Diabetic neuropathy: Mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014;14:473. - DOI - PubMed - PMC
    1. Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019;19:86. - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources